Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: A preliminary report

Urology

Volumn 59, Issue 3, 2002, Pages 394-398

  Uchida, Toyoaki ^a   Sanghvi, Narendra T ^b   Gardner, Thomas A ^c   Koch, Michael O ^c   Ishii, Daisuke ^a   Minei, Sadanori ^a   Satoh, Takefumi ^a   Hyodo, Toru ^a   Irie, Akira ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Focus Surgery Incorporated   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM FISTULA; SURGICAL TECHNIQUE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TUMOR BIOPSY; URETHRA STRICTURE; URINE RETENTION;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; LENGTH OF STAY; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; ULTRASONIC THERAPY;

EID: 0036188362     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01624-7     Document Type: Article

References (27)

1. Cancer statistics, 1999
2. Radical retropubic prostatectomy; time trends, morbidity and mortality in Japan
3. Ability of the 1992-1997 American Joint Committee on Cancer Staging for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease
4. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer; continued risk of biochemical failure after 5 years
5. Radiation-associated morbidity in patients undergoing small-field external beam radiation for prostate cancer
6. Radiation therapy for clinically localized prostate cancer; a multi-institutional pooled analysis
7. A comprehensive review of prostate cancer brachytherapy; defining an optional technique
8. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
9. Prostate cryoablation; update 1998
10. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostate cancer
11. Current status of minimally invasive treatment options for localized prostate carcinoma
12. Laparoscopic radical prostatectomy; the Montsouris experience
13. Clinical outcome of high-intensity focused ultrasound for treating benign prostatic hyperplasia; preliminary report
14. Experimental studies of using of split beam transducer for prostate cancer therapy in comparison to single beam transducer
15. Effect of high-intensity focused ultrasound on human prostate cancer in vivo
16. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
17. Consensus statement; guidelines for PSA following radiation therapy
18. Transrectal high-intensity focused ultrasound; minimally invasive therapy of localized prostate cancer
19. Treatment of prostate cancer with transrectal focused ultrasound; early clinical experience
20. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy; preliminary report
21. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma
22. High-intensity focused ultrasound in localized prostate cancer
23. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer; a multi-institutional update
24. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy; results of a prospective study
25. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localized adenocarcinoma of the prostate